

Patient	Evaluation phase	Study type	Age	Gender	Treatment	Pre-treatment Serum PSA	T-stage	N-stage	M-stage	Gleason Score	Gleason Grade
1	BCT evaluation	Proteomics	71	M	RP + PLND	15,2	pT3b	pN0	cM0	5+4	5
2	BCT evaluation	Proteomics	66	M	RP + PLND	12,3	pT2c	pN0	cM0	3+4	2
3	BCT evaluation	Proteomics	68	M	RP + PLND	4,4	pT3a	pN0	cM0	4+4	4
4	BCT evaluation	RNA sequencing	75	M	RP + PLND	9,24	pT2c	pN0	cM0	3+4	2
5	BCT evaluation	RNA sequencing	64	M	sPLND	1.8	NA	pN1	cM0	NA	NA
6	BCT evaluation	RNA sequencing	70	M	RP + PLND	223	pT3b	pN1	cM0	4+5	5
7	BPI evaluation	Proteomics	68	M	RP	8	pT2a	pN0	cM0	3+3	1
8	BPI evaluation	Proteomics	70	M	RP + PLND	12,5	pT2a	pN0	cM0	3+4	2
9	BPI evaluation	Proteomics	55	M	RP	9,1	pT2b	pN0	cM0	3+3	1
10	BPI evaluation	RNA sequencing	52	M	RP	6,2	pT2a	pN0	cM0	3+4	2
11	BPI evaluation	RNA sequencing	62	M	RP + PLND	10,3	pT2b	pN0	cM0	4+3	3
12	BPI evaluation	RNA sequencing	50	M	RP	6,1	pT2c	pN0	cM0	3+4	2

Supplementary table 2: Patient characteristics. Abbreviations: RP: radical prostatectomy, (s)PLND: (salvage) PLND, PSA: prostate specific antigen.